Optimizing a therapeutic humanized follicle-stimulating hormone–blocking antibody formulation by protein thermal shift assay

Damini Sant, Satish Rojekar, Sakshi Gera, Anusha R. Pallapati, Judit Gimenez-Roig, Tan Chun Kuo, Ashley Padilla, Funda Korkmaz, Liam Cullen, Jiya Chatterjee, Eleanor Shelly, Marcia Meseck, Sari Miyashita, Anne Macdonald, Farhath Sultana, Orly Barak, Vitaly Ryu, Se Min Kim, Cemre Robinson, Clifford J. RosenJohn Caminis, Daria Lizneva, Shozeb Haider, Tony Yuen, Mone Zaidi

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Biopharmaceutical products are formulated using several Food and Drug Administration (FDA) approved excipients within the inactive ingredient limit to maintain their storage stability and shelf life. Here, we have screened and optimized different sets of excipient combinations to yield a thermally stable formulation for the humanized follicle-stimulating hormone (FSH)–blocking antibody, MS-Hu6. We used a protein thermal shift assay in which rising temperatures resulted in the maximal unfolding of the protein at the melting temperature (Tm). To determine the buffer and pH for a stable solution, four different buffers with a pH range from 3 to 8 were screened. This resulted in maximal Tms at pH 5.62 for Fab in phosphate buffer and at pH 6.85 for Fc in histidine buffer. Upon testing a range of salt concentrations, MS-Hu6 was found to be more stable at lower concentrations, likely due to reduced hydrophobic effects. Molecular dynamics simulations revealed a higher root-mean-square deviation with 1 mM than with 100 mM salt, indicating enhanced stability, as noted experimentally. Among the stabilizers tested, Tween 20 was found to yield the highest Tm and reversed the salt effect. Among several polyols/sugars, trehalose and sucrose were found to produce higher thermal stabilities. Finally, binding of recombinant human FSH to MS-Hu6 in a final formulation (20 mM phosphate buffer, 1 mM NaCl, 0.001% w/v Tween 20, and 260 mM trehalose) resulted in a thermal shift (increase in Tm) for the Fab, but expectedly not in the Fc domain. Given that we used a low dose of MS-Hu6 (1 μM), the next challenge would be to determine whether 100-fold higher, industry-standard concentrations are equally stable.

Original languageEnglish
Pages (from-to)67-78
Number of pages12
JournalAnnals of the New York Academy of Sciences
Issue number1
StatePublished - Mar 2023


  • FSH
  • Good Laboratory Practice (GLP)
  • antibody development
  • biotherapeutics
  • colloidal stability


Dive into the research topics of 'Optimizing a therapeutic humanized follicle-stimulating hormone–blocking antibody formulation by protein thermal shift assay'. Together they form a unique fingerprint.

Cite this